# Signals Article: Putative Target P02766 for Transthyretin Amyloid Cardiomyopathy
Background
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening condition characterized by the deposition of amyloid fibrils derived from transthyretin (TTR) in the heart, leading to restrictive cardiomyopathy and heart failure. ATTR-CM is often underdiagnosed and has limited treatment options, making the identification of novel therapeutic targets crucial for improving patient outcomes.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P02766, which encodes transthyretin, was identified as a putative target for ATTR-CM. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically dataset GDS:200067784. Although P02766 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
The GEO dataset containing P02766 predates modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P02766's potential as a target for ATTR-CM. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P02766 as a target for ATTR-CM, several steps are recommended. Re-analyzing the matched GEO dataset using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of ATTR-CM. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P02766. If validated, assessing the druggability of P02766 via DGIdb and ChEMBL will be crucial for potential therapeutic development.